First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.
Fiche publication
Date publication
juin 2021
Journal
Future oncology (London, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr SCHOTT Roland
Tous les auteurs :
Descourt R, Chouaid C, Pérol M, Besse B, Greillier L, Bylicki O, Ricordel C, Guisier F, Gervais R, Schott R, Auliac JB, Robinet G, Decroisette C
Lien Pubmed
Résumé
Pembrolizumab plus chemotherapy is currently used in the first-line treatment of advanced non-small-cell lung cancer without mutations or rearrangements, regardless of PD-L1 expression status. A study comparing chemotherapy plus pembrolizumab versus pembrolizumab alone has never been performed in patients with PD-L1 ≥50%. The aim of this trial is to perform such a comparison as first-line treatment in patients not eligible for locally advanced treatment who have expression of PD-L1 on ≥50% of tumor cells. The expected results are a reduction in the risk of early progression. A higher objective tumor response is also expected with the combination of chemotherapy and pembrolizumab compared with pembrolizumab alone. The study will allow a direct comparison of the proportion of patients who derive long-term benefit from the treatment. EudraCT (2020-002626-86); ClinicalTrials.gov (NCT04547504).
Mots clés
PD-L1, Phase III trial, first-line setting, non-small-cell lung cancer, pembrolizumab, randomized study
Référence
Future Oncol. 2021 Jun 22;: